BIO5 Partners with Collaborative Drug Discovery to Manage Burgeoning Internal Compound Collection

BIO5 Partners with Collaborative Drug Discovery to Manage Burgeoning Internal Compound Collection

press-release-stock

 

TUCSON, Ariz., March 28, 2013 — The University of Arizona’s BIO5 Institute Oro Valley (BIO5-OV) has partnered with Collaborative Drug Discovery (CDD), Inc. to use the CDD Vault, a state-of-the-art cloud technology, to capture and securely share BIO5’s drug discovery research data. BIO5-OV uses the CDD Vault to manage BIO5-OV’s expanding large compound collection and corresponding bioactivity data. A unique resource in the state of Arizona, the BIO5 Oro Valley small molecule compound collection (>100,000 compounds) has been established as a regional resource to help kick-start drug discovery campaigns.

Dr. Christopher Hulme, Prof. of Pharmacology and Toxicology at the University of Arizona and Co-director of BIO5 Oro Valley had this to say:

We are delighted to have CDD as a partner and its technology as part of our infrastructure to help us achieve our scientific and collaborative goals.  We need a well-established, robust, easy-to-use platform to enable us to capture all the new chemical, biological, and computational data our scientists generate and ensure all our high-value information and newly generated intellectual property is never lost in the fast-paced drug discovery activities taking place at BIO5-OV,

We have a well-curated and continuously expanding compound collection to support research projects and drug discovery campaigns, where scientists at the University of Arizona can deposit their high-value compounds for storage, record-keeping, reformatting and distribution to collaborators. We also complement and enrich the quality of our compound collection by carefully selecting and acquiring compounds either via purchasing or through strategic partnerships.  Having the right platform to record, track and manage this process effectively and securely gives us a great research and operational advantage, said Dr. Guillermo A. Morales, in charge of BIO5-OV’s compound management and collection.

“BIO5 brings the best of industry and academic scientists together for translational research,” mentioned CDD CEO Dr. Barry A. Bunin:

In addition to bringing the CDD Vault onboard, the people at BIO5 have proved to be technology trailblazers, and have become early adopters of the novel CDD Vault Enterprise edition with extensions. These new extensions will enable BIO5 to link their core CDD Vault database to other in-house and external software, creating a complete and integrated solution. There is a growing ecosystem of companies and technologies around CDD, creating a modern approach and full solution for enlightened, budget sensitive drug discovery researchers.

About BIO5 Oro Valley

The University of Arizona’s BIO5 Oro Valley is the State’s translational drug discovery and development center which is focused on bringing new therapies to patients.  The center houses an extensive library of over 100,000 compounds to partner with disease biologists to find new potential drugs and manage the drug discovery and development process through to IND filing. For more information, visit www.bio5orovalley.org

BIO5 Oro Valley Press Contact
Nina Ossanna, Ph.D.
Co-Director, BIO5 Oro Valley
nossanna@email.arizona.edu

About Collaborative Drug Discovery, Inc.

CDD (www.collaborativedrug.com) provides the most widely used web-based drug discovery software platform on the market. “CDD Vault™” is the secure, private industrial-strength database combining traditional drug discovery informatics (registration and SAR) with social networking capabilities. “CDD Collaborate™” enables real-time collaboration by securely exchanging selected confidential data with external researchers. “CDD Public™” enables researchers to mine a unique aggregation of information from a variety of scientific data providers.

Collaborative Drug Discovery Press Contact
Sylvia Ernst, Ph.D.
Sr. Director, Community Growth
sylvia@collaborativedrug.com